Transcriptomics

Dataset Information

0

Bendamustine combined with rituximab induces pyroptosis to shape an "immunologically hot" tumor microenvironment in DLBCL cells via the STING pathway


ABSTRACT: Bendamustine plus rituximab (BR) therapy has demonstrated favorable clinical outcomes in the treatment of DLBCL patients who are intolerant to R-CHOP therapy. In vitro, BR therapy exhibits a synergistic cytotoxic effect on DLBCL cell lines. Mechanistically, BR induces pyroptosis in DLBCL cells by activating the cGAS-STING pathway, leading to the release of inflammatory factors and the formation of an "immunologically hot" microenvironment. Additionally, BR therapy upregulates MHC molecules on the tumor cell surface, thereby augmenting T cell activation and function.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249466 | GEO | 2024/08/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA1049338 | ENA
2008-12-05 | E-GEOD-10846 | biostudies-arrayexpress
2008-11-28 | GSE10846 | GEO
2021-01-03 | GSE159852 | GEO
2022-04-26 | E-MTAB-11611 | biostudies-arrayexpress
2023-08-13 | GSE240328 | GEO
2023-10-22 | GSE211829 | GEO
2012-08-01 | GSE31312 | GEO
2012-04-09 | E-GEOD-37107 | biostudies-arrayexpress
2019-09-10 | GSE37107 | GEO